Despite positive clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is here experiencing significant resistance from PBMs. Such insurers are often building obstacles to reimbursement, like steep expense requirements and prior authorization that restrict consumer availability. Market indicate